Sanjay Iyer, MD
Neurology · Charlotte, NCNPI 1376561472
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $469,399 of the $580,683 with a category attached, or 80.8%. 21 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 35.2% of the total. Among neurology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 893 payments — averaging $650.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$204K
- MDD US Operations, LLC$173K
- Teva Pharmaceuticals USA, Inc.$88K
- Acorda Therapeutics, Inc$44K
- Kyowa Kirin, Inc.$38K
- Adamas Pharmaceuticals, Inc.$21K
- plus $14K from 15 others
Across 4 payments — averaging $26,078 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$101K
- H. Lundbeck A S$3K
What the payments were for
- Consulting fees$63,37311%
- Speaking & faculty fees$469,39981%
- Travel & lodging$33,9516%
- Food & beverage$12,3612%
- Education$1,6000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 239 | $204,303 |
| MDD US Operations, LLC | 359 | $172,697 |
| Teva Pharmaceuticals USA, Inc. | 104 | $87,804 |
| Acorda Therapeutics, Inc | 40 | $43,510 |
| Kyowa Kirin, Inc. | 32 | $38,044 |
| Adamas Pharmaceuticals, Inc. | 14 | $20,674 |
| Sunovion Pharmaceuticals Inc. | 22 | $8,810 |
| AbbVie(2 entities) | 28 | $2,200 |
| Amneal Pharmaceuticals LLC | 11 | $1,591 |
| Merz Pharmaceuticals, LLC | 11 | $332 |
| Acadia Pharmaceuticals Inc | 13 | $266 |
| Pfizer | 5 | $104 |
| Otsuka America Pharmaceutical, Inc. | 4 | $98 |
| GE HealthCare | 2 | $54 |
| Lundbeck LLC | 2 | $41 |
| Revance Therapeutics, Inc. | 1 | $34 |
| Avanir Pharmaceuticals, Inc. | 2 | $31 |
| Merz North America, Inc. | 1 | $31 |
| Eisai Inc. | 1 | $27 |
| Boston Scientific | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$193,846
- GOCOVRI$78,379
- AUSTEDO$46,460
- INBRIJA$42,986
- Austedo XR$40,591
- NOURIANZ$37,741
- APOKYN$30,198
- MYOBLOC$16,858
- KYNMOBI$7,000
- ONGENTYS$5,608
- VYALEV$1,602
- LONHALA MAGNAIR$1,500
- ONGENTYS 50MG CAPSULES 30$932
- Duopa$125
How this compares
$580,683 in reported general payments places this provider in the 95th percentile of 566 neurology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 67 | $351,712 |
| GocovriAmantadine Hcl | 97 | $315,528 |
| RytaryCarbidopa/Levodopa | 112 | $181,448 |
| Austedo XrDeutetrabenazine | 12 | $173,207 |
| NourianzIstradefylline | 71 | $150,517 |
| IngrezzaValbenazine Tosylate | 13 | $110,405 |
| AustedoDeutetrabenazine | 19 | $88,990 |
| InbrijaLevodopa | 17 | $87,913 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 581 | $26,648 |
| NeuproRotigotine | 27 | $25,632 |
| OngentysOpicapone | 15 | $18,192 |
| CrexontCarbidopa/Levodopa | 20 | $16,436 |
| TrintellixVortioxetine Hydrobromide | 18 | $9,686 |
| Rasagiline Mesylate | 78 | $7,618 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 153 | $6,470 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $266 | $351,71267 claims |
| MDD US Operations, LLCGocovri | $172,697 | $315,52897 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $87,804 | $262,19731 claims |
| Amneal Pharmaceuticals LLCRytary, Crexont | $1,591 | $197,884132 claims |
| Kyowa Kirin, Inc.Nourianz | $38,044 | $150,51771 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $204,303 | $128,59728 claims |
| Acorda Therapeutics, IncInbrija | $43,510 | $87,91317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 566 neurology providers in North Carolina.
Other neurology in Charlotte
- Jill ConwayCharlotte$1M
- Matthew CarraroCharlotte$695K
- Megan DonnellyCharlotte$601K
- Urvi DesaiCharlotte$262K
- Danielle Englert DoggettCharlotte$215K
- Robert WigginsCharlotte$138K
- Ardith CourtneyCharlotte$120K
- Joseph ChipmanCharlotte$118K
- Kurt WashburnCharlotte$66K
- Ziad HageCharlotte$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.